Compare Stocks: ALNY, MRNA, REGN, and NTRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$227.28 +1.0%	$239.89	$197.81 ▼ $485.36	$30.41B	0.28	1.44 million shs	2.21 million shs
MRNA Moderna	$202.63 -17.6%	$167.27	$22.28 ▼ $254.48	$80.90B	1.09	12.60 million shs	49.76 million shs
NTRA Natera	$401.37 -2.9%	$363.64	$181.00 ▼ $437.41	$57.86B	1.5	1.40 million shs	1.61 million shs
REGN Regeneron Pharmaceuticals	$819.09 +1.7%	$791.56	$572.75 ▼ $859.34	$84.33B	0.16	817,917 shs	852,262 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-2.43%	+0.28%	-7.87%	-16.24%	-52.51%
MRNA Moderna	+1.54%	+8.62%	+42.14%	+331.09%	+794.18%
NTRA Natera	+1.84%	+4.72%	+11.53%	+56.18%	+121.20%
REGN Regeneron Pharmaceuticals	-0.22%	+3.51%	+0.94%	+23.59%	+39.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$227.28 +1.0%	$239.89	$197.81 ▼ $485.36	$30.41B	0.28	1.44 million shs	2.21 million shs
MRNA Moderna	$202.63 -17.6%	$167.27	$22.28 ▼ $254.48	$80.90B	1.09	12.60 million shs	49.76 million shs
NTRA Natera	$401.37 -2.9%	$363.64	$181.00 ▼ $437.41	$57.86B	1.5	1.40 million shs	1.61 million shs
REGN Regeneron Pharmaceuticals	$819.09 +1.7%	$791.56	$572.75 ▼ $859.34	$84.33B	0.16	817,917 shs	852,262 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-2.43%	+0.28%	-7.87%	-16.24%	-52.51%
MRNA Moderna	+1.54%	+8.62%	+42.14%	+331.09%	+794.18%
NTRA Natera	+1.84%	+4.72%	+11.53%	+56.18%	+121.20%
REGN Regeneron Pharmaceuticals	-0.22%	+3.51%	+0.94%	+23.59%	+39.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.92	Moderate Buy	$364.95	60.41% Upside
MRNA Moderna	2.12	Hold	$103.95	-44.99% Downside
NTRA Natera	2.78	Moderate Buy	$374.64	-5.10% Downside
REGN Regeneron Pharmaceuticals	2.77	Moderate Buy	$846.28	3.38% Upside

Current Analyst Ratings Breakdown

Latest ALNY, MRNA, REGN, and NTRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/21/2026	MRNA Moderna	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/21/2026	MRNA Moderna	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Hold	$40.00 ➝ $90.00
10/21/2026	REGN Regeneron Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$960.00 ➝ $980.00
10/19/2026	NTRA Natera	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$375.00 ➝ $500.00
10/19/2026	REGN Regeneron Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$854.00 ➝ $865.00
10/16/2026	NTRA Natera	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/15/2026	NTRA Natera	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	ALNY Alnylam Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$550.00 ➝ $354.00
10/15/2026	MRNA Moderna	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$120.00 ➝ $137.00
10/15/2026	REGN Regeneron Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$660.00 ➝ $978.00
10/14/2026	ALNY Alnylam Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy

(Data available from 10/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$4.80B	6.34	$2.76 per share	82.51	$5.97 per share	38.11
MRNA Moderna	$1.94B	38.81	N/A	N/A	$22.14 per share	8.54
NTRA Natera	$2.71B	21.02	N/A	N/A	$12.38 per share	31.89
REGN Regeneron Pharmaceuticals	$15.53B	5.43	$42.55 per share	19.24	$295.66 per share	2.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	42.46	23.67	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/6/2026 (Estimated)
NTRA Natera	-$208.16M	-$1.36	N/A	N/A	N/A	-7.11%	-11.38%	-7.87%	11/5/2026 (Estimated)
REGN Regeneron Pharmaceuticals	$4.50B	$40.46	20.27	15.46	1.37	27.86%	13.47%	10.34%	10/30/2026 (Estimated)

Latest ALNY, MRNA, REGN, and NTRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	Q3 2026	MRNA Moderna	-$1.07	N/A	N/A	N/A	$892.41 million	N/A
11/5/2026	Q3 2026	NTRA Natera	-$0.2697	N/A	N/A	N/A	$707.67 million	N/A
10/30/2026	Q3 2026	REGN Regeneron Pharmaceuticals	$16.19	N/A	N/A	N/A	$4.56 billion	N/A
10/29/2026	Q3 2026	ALNY Alnylam Pharmaceuticals	$1.70	N/A	N/A	N/A	$1.43 billion	N/A
8/6/2026	Q2 2026	NTRA Natera	-$0.4939	-$0.47	+$0.0239	-$0.47	$661.24 million	$752.75 million
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion
7/30/2026	Q2 2026	REGN Regeneron Pharmaceuticals	$10.16	$14.29	+$4.13	$12.23	$3.82 billion	$4.29 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.76	0.46%	N/A	9.29%	N/A

Latest ALNY, MRNA, REGN, and NTRA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.46%	8/18/2026	8/18/2026	8/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
MRNA Moderna	0.09	2.29	2.18
NTRA Natera	N/A	3.00	2.85
REGN Regeneron Pharmaceuticals	0.06	3.34	2.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
MRNA Moderna	75.33%
NTRA Natera	99.90%
REGN Regeneron Pharmaceuticals	83.31%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
MRNA Moderna	10.80%
NTRA Natera	5.05%
REGN Regeneron Pharmaceuticals	6.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable
NTRA Natera	6,140	144.14 million	136.87 million	Optionable
REGN Regeneron Pharmaceuticals	15,410	102.96 million	95.78 million	Optionable

ALNY, MRNA, REGN, and NTRA Headlines

Recent News About These Companies

Regeneron: Is The Market Undervaluing Its Growth Potential

October 22 at 10:00 AM | seekingalpha.com

Regeneron Pharmaceuticals, Inc. $REGN Stock Bought by Vest Financial LLC

October 22 at 6:08 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. $REGN Shares Newly Bought by Cantor Fitzgerald Investment Advisors L.P.

October 22 at 3:27 AM | marketbeat.com

Are You Overpaying For Regeneron Stock Versus Its Rivals?

October 21 at 10:23 PM | trefis.comT

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Bump from TD Cowen

October 21 at 11:23 AM | marketbeat.com

Robeco Institutional Asset Management B.V. Sells 57,644 Shares of Regeneron Pharmaceuticals, Inc. $REGN

October 21 at 5:35 AM | marketbeat.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Piper Sandler Analyst Says

October 21 at 1:42 AM | americanbankingnews.com

How Much Upside Is Left In Regeneron Stock?

October 19 at 5:27 PM | trefis.comT

Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial Results

October 19 at 5:27 PM | finance.yahoo.com

Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial Results

October 19 at 2:51 PM | insidermonkey.com

Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by BDF Gestion

October 19 at 1:04 PM | marketbeat.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $865.00 Price Target at Piper Sandler

October 19 at 12:29 PM | marketbeat.com

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market

October 19 at 10:24 AM | fool.com

Regeneron's Murphy sells $3.2 million in stock under plan (NASDAQ: REGN)

October 19 at 4:04 AM | americanbankingnews.com

Regeneron Pharmaceuticals, Inc. $REGN Stock Sold by Assenagon Asset Management S.A.

October 19 at 3:11 AM | marketbeat.com

10,570 Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Vontobel Holding Ltd.

October 18, 2026 | marketbeat.com

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share

October 17, 2026 | fool.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Raised to Buy at UBS Group

October 17, 2026 | americanbankingnews.com

CHMP backs wider dosing gap for Regeneron’s Libtayo

October 16, 2026 | financial-news.co.uk

Regeneron's Libtayo Wins EMA CHMP Support For Extended Dosing

October 16, 2026 | rttnews.com

Regeneron Pharmaceuticals (NASDAQ:REGN): What Changes After Its Latest Company Update?

October 16, 2026 | kalkinemedia.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALNY, MRNA, REGN, and NTRA Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$227.28 +2.18 (+0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$227.52 +0.24 (+0.11%)

As of 06:04 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Moderna NASDAQ:MRNA

$202.63 -43.18 (-17.57%)

Closing price 04:00 PM Eastern

Extended Trading

$199.79 -2.84 (-1.40%)

As of 06:06 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Natera NASDAQ:NTRA

$401.37 -12.01 (-2.91%)

Closing price 04:00 PM Eastern

Extended Trading

$401.32 -0.05 (-0.01%)

As of 05:51 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Regeneron Pharmaceuticals NASDAQ:REGN

$819.09 +13.42 (+1.67%)

Closing price 04:00 PM Eastern

Extended Trading

$817.45 -1.64 (-0.20%)

As of 06:01 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALNY, MRNA, REGN, and NTRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALNY, MRNA, REGN, and NTRA Earnings

Compare Dividends

Latest ALNY, MRNA, REGN, and NTRA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALNY, MRNA, REGN, and NTRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALNY, MRNA, REGN, and NTRA Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Moderna NASDAQ:MRNA

Natera NASDAQ:NTRA

Regeneron Pharmaceuticals NASDAQ:REGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools